• Aurigene.AI is an end-to-end solution for small molecule drug discovery combining AI and ML capabilities with Aurigene’s core expertise in synthesizing and testing the molecules in vitro and in vivo.

• The platform consists of a meticulously curated database that serves as training data.

• The modular platform allows users flexibility in selecting suitable AI models from a set of generative, predictive, and computational algorithms. It utilizes an iterative ML process for rational and efficient chemical design, and prioritization based on synthetic tractability and properties such as ADME (Absorption, Distribution, Metabolism, Excretion) and potency. 

HYDERABAD, India–(BUSINESS WIRE)–Aurigene Pharmaceutical Services Limited (Aurigene), a contract research, development, and manufacturing services organization and a Dr. Reddy’s Laboratories company, introduces Aurigene.AI, an AI and ML-assisted platform for accelerating drug discovery projects from hit identification to candidate nomination. 

Aurigene.AI combines advanced physics-based simulation, generative and predictive AI models, and CADD (Computer-Aided Drug Design) in one platform, allowing users to pick the appropriate algorithms for a given application. The modular platform also consists of a meticulously curated database of 180 million compounds and 1.6 million validated bioassay data points. This database is ever-expanding and serves as training data for the platform. Read more >